Acne Treatment Market Global Industry Growth, Revenue Insights, and Forecast 2032

The acne treatment market is steadily expanding, driven by the global prevalence of acne across all age groups and evolving consumer needs for effective skincare solutions. Products span topical agents like retinoids, antibiotics, and over-the-counter formulations to oral therapies and innovative combination treatments. North America remains the largest market, but regions such as Asia-Pacific are growing rapidly due to rising aesthetic awareness and broader access to dermatological care. Key trends include the emergence of multi-ingredient products, personalized regimens, natural or organic ingredients, remote teledermatology, and digital engagement. While affordability and efficacy challenges persist, ongoing innovation and digital integration promise to sustain momentum in the market's evolution.

According to Fortune Business Insights, the global acne treatment market share was valued at USD 11.62 billion in 2024 and is projected to grow from USD 12.19 billion in 2025 to USD 17.48 billion by 2032, exhibiting a CAGR of 5.3% during the forecast period. North America dominated the acne treatment market with a market share of 49.14% in 2023.

Top Companies in the Market

• ABBVIE INC. (Ireland)

• Botanix Pharmaceuticals (Australia)

• GALDERMA (Switzerland)

• Bausch Health Companies Inc. (U.S.)

• GlaxoSmithKline Plc. (U.K.)

• Bayer AG (Germany)

• Johnson & Johnson Services, Inc. (U.S.)

• Pfizer Inc. (U.S.)

• Teva Pharmaceutical Industries Ltd. (Israel)

Market Overview at a Glance

The report covers a comprehensive analysis of the acne treatment market from 2019 to 2032. Key features include:

• Market size & forecast (2019–2032), with 2024 as the base year

• Segmentation by product type, route of administration, age group, distribution channel, and region/country

• Country-level breakdown for regions including U.S., Canada, U.K., Germany, France, Italy, Spain, China, Japan, India, Australia, Southeast Asia, Brazil, Mexico, GCC, South Africa

• New product launches, pipeline analysis, and technological developments

• Overview of leading companies and competitive strategies including inorganic growth like acquisitions and licensing agreements

Key Industry Development

In October 2023, tbh Skincare signed an agreement with Coles, one of Australia’s supermarket giants, to launch its acne treatment product in 857 Coles stores nationwide.

Market Drivers & Restraints

The rising global prevalence of skin disorders is a critical driver fueling the demand for acne treatment solutions. Acne affects approximately 9.4% of the global population as of 2022, making it the eighth most widespread disease worldwide. This prevalence, combined with increasing aesthetic concerns and strong focus by key players on launching innovative products, is propelling market growth.

One notable trend supporting the market is the continuous approval and launch of novel acne treatments. For example, in October 2023, Crown Therapeutics introduced two new products—PanOxyl Adapalene 0.1% Gel and PanOxyl Clarifying Exfoliant—to broaden its acne portfolio. Similarly, in October 2023, the U.S. FDA approved IDP-126 (Cabtreo) by Bausch Health—the first fixed-dose, triple-combination topical treatment for acne.

However, the market faces challenges. Drug-associated side effects such as nausea, vomiting, or diarrhea occur in approximately 7% of patients on tetracycline and 4% on macrolides. Additionally, antibiotic resistance remains a concern—with more than 2.8 million people in the U.S. encountering antibiotic resistance, potentially limiting long-term market growth. FDA alerts concerning OTC medications capable of causing severe allergic reactions or irritation further restrict adoption.

Market Segmentation

By Product Type

The market is segmented into antibiotics, retinoids, isotretinoin, and others. The antibiotics segment holds the current dominant share due to its high efficiency and frequent clinical approvals. Meanwhile, the retinoids segment is expected to register the highest CAGR by 2032, driven by rising demand for treating moderate to severe acne.

By Route of Administration

The market divides into topical and oral routes. The topical segment dominates in 2024, thanks to the convenience and wide availability of OTC topical solutions. The oral segment is projected to grow significantly, spurred by increasing product launches like Seysara, an oral antibiotic launched by Almirall in the U.S. in January 2019.

By Age Group

Age segments include 10-17 years, 18-44, 45-64, and 65+ years. The 18–44 years group is expected to dominate market share, reflecting a growing incidence of adult acne—affecting around 40% of adults. The teenage segment (10–17 years) is also growing, driven by rising cases of acne vulgaris.

By Distribution Channel

Distribution is divided between retail & online pharmacies and hospital pharmacies. The retail & online segment is poised for lucrative growth, thanks to the proliferation of e-commerce platforms—like Amazon and Walmart—offering OTC acne treatments. Hospital pharmacies continue to hold significant share due to increasing clinical consultations for acne treatment.

Explore the full research report with detailed insights and TOC:https://www.fortunebusinessinsights.com/acne-treatment-market-103361 

Market Regional Insights

Based on region, the market is segmented into North America, Europe, Asia Pacific.

In 2024, North America led the market with a value of USD 5.70 billion. This dominance stems from high prevalence, increasing aesthetic concerns, strong product launches, and brand presence.

Europe ranks second, backed by an expanding patient base, significant R&D investment, and growing adoption of advanced dermatology treatments.

The Asia Pacific region is expected to exhibit the highest CAGR, driven by rising consumer awareness and expanding presence of pharmaceutical companies in markets such as Australia, Japan, and New Zealand (e.g., Sun Pharma’s collaboration with Cassiopea to bring Winlevi to these countries in July 2022).

Summary & Future Outlook

With a base valuation of USD 11.62 billion in 2024, the acne treatment market is on a steady upward trajectory, projected to reach USD 17.48 billion by 2032 (CAGR: 5.3%). North America maintains the largest market share, while Asia Pacific emerges as the fastest-growing region. The antibiotics segment currently dominates, although retinoids are expected to gain pace. Topical administration remains the preferred mode, particularly via retail and online pharmacies, while the adult segment (18–44 years) represents a significant portion of demand.

About Us:Fortune Business Insights provides expert corporate analysis and accurate data, enabling businesses of all sizes to make timely decisions. We offer customized solutions tailored to each client’s needs, helping them address unique challenges. Our goal is to empower clients with holistic market intelligence and offer granular insights into the market they operate in.

At Fortune Business Insights, we aim to highlight growth opportunities for our clients, offering insights and recommendations that help them navigate technological and market changes. Our consulting services are designed to help companies uncover hidden opportunities and address competitive challenges.

Contact us:

Fortune Business Insights™ Pvt.

Phone: USA: +1 833 909 2966 (Toll-Free),

United Kingdom: +44 808 502 0280 (Toll-Free),

APAC: +91 744 740 1245

Email: sales@fortunebusinessinsights.com